Literature DB >> 19620399

The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry.

Hemant Kulkarni1, Vincent C Marconi, Weijing He, Michael L Landrum, Jason F Okulicz, Judith Delmar, Dickran Kazandjian, John Castiblanco, Seema S Ahuja, Edwina J Wright, Robin A Weiss, Robert A Clark, Matthew J Dolan, Sunil K Ahuja.   

Abstract

Persons of African ancestry, on average, have lower white blood cell (WBC) counts than those of European descent (ethnic leukopenia), but whether this impacts negatively on HIV-1 disease course remains unknown. Here, in a large natural history cohort of HIV-infected subjects, we show that, although leukopenia (< 4000 WBC/mm(3) during infection) was associated with an accelerated HIV disease course, this effect was more prominent in leukopenic subjects of European than African ancestry. The African-specific -46C/C genotype of Duffy Antigen Receptor for Chemokines (DARC) confers the malaria-resisting, Duffy-null phenotype, and we found that the recently described association of this genotype with ethnic leukopenia extends to HIV-infected African Americans (AAs). The association of Duffy-null status with HIV disease course differed according to WBC but not CD4(+) T-cell counts, such that leukopenic but not nonleukopenic HIV(+) AAs with DARC -46C/C had a survival advantage compared with all Duffy-positive subjects. This survival advantage became increasingly pronounced in those with progressively lower WBC counts. These data highlight that the interaction between DARC genotype and the cellular milieu defined by WBC counts may influence HIV disease course, and this may provide a partial explanation of why ethnic leukopenia remains benign in HIV-infected AAs, despite immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620399      PMCID: PMC2927046          DOI: 10.1182/blood-2009-04-215186

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation.

Authors:  Janet S Lee; Mark M Wurfel; Gustavo Matute-Bello; Charles W Frevert; Matthew R Rosengart; Mrunalini Ranganathan; Venus W Wong; Tarah Holden; Steve Sutlief; Ann Richmond; Stephen Peiper; Thomas R Martin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  White blood cell counts in Plasmodium vivax malaria.

Authors:  Alfonso J Rodríguez-Morales; Elia Sánchez; Melissa Arria; Miguel Vargas; Carmelina Piccolo; Rosa Colina; Carlos Franco-Paredes
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

Review 3.  Contribution of Duffy antigen to chemokine function.

Authors:  Antal Rot
Journal:  Cytokine Growth Factor Rev       Date:  2005-07-27       Impact factor: 7.638

4.  Effectiveness of highly-active antiretroviral therapy by race/ethnicity.

Authors:  Michael J Silverberg; Scott A Wegner; Mark J Milazzo; Rosemary G McKaig; Carolyn F Williams; Brian K Agan; Adam W Armstrong; Stephen J Gange; Clifton Hawkes; Robert J O'Connell; Sunil K Ahuja; Matthew J Dolan
Journal:  AIDS       Date:  2006-07-13       Impact factor: 4.177

5.  Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.

Authors:  W Keith Henry; Pablo Tebas; H Clifford Lane
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

6.  Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study.

Authors:  Alexandra M Levine; Roksana Karim; Wendy Mack; D Jay Gravink; Katherine Anastos; Mary Young; Mardge Cohen; Meg Newman; Michael Augenbraun; Stephen Gange; D Heather Watts
Journal:  Arch Intern Med       Date:  2006-02-27

7.  CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.

Authors:  Matthew J Dolan; Hemant Kulkarni; Jose F Camargo; Weijing He; Alison Smith; Juan-Manuel Anaya; Toshiyuki Miura; Frederick M Hecht; Manju Mamtani; Florencia Pereyra; Vincent Marconi; Andrea Mangano; Luisa Sen; Rosa Bologna; Robert A Clark; Stephanie A Anderson; Judith Delmar; Robert J O'Connell; Andrew Lloyd; Jeffrey Martin; Seema S Ahuja; Brian K Agan; Bruce D Walker; Steven G Deeks; Sunil K Ahuja
Journal:  Nat Immunol       Date:  2007-10-21       Impact factor: 25.606

Review 8.  HIV disease progression: immune activation, microbes, and a leaky gut.

Authors:  Daniel Douek
Journal:  Top HIV Med       Date:  2007 Aug-Sep

9.  The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment.

Authors:  Seiji Fukuda; Huimin Bian; Andrew G King; Louis M Pelus
Journal:  Blood       Date:  2007-04-06       Impact factor: 22.113

Review 10.  Duffy blood group and malaria.

Authors:  Dante M Langhi; José Orlando Bordin
Journal:  Hematology       Date:  2006-10       Impact factor: 2.269

View more
  23 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

Review 2.  Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.

Authors:  Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

3.  Double-edged genetic swords and immunity: lesson from CCR5 and beyond.

Authors:  Sunil K Ahuja; Weijing He
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

4.  Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity.

Authors:  S J Glisovic; Y D Pastore; V Gagne; M Plesa; C Laverdière; J M Leclerc; D Sinnett; M Krajinovic
Journal:  Pharmacogenomics J       Date:  2017-05-23       Impact factor: 3.550

5.  Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.

Authors:  Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Emanuela Taioli; Jay H Fowke; Stephen J Freedland
Journal:  Cancer Causes Control       Date:  2018-04-17       Impact factor: 2.506

6.  CD235a (Glycophorin-A) Is the Most Predictive Value Among Different Circulating Cellular Microparticles in Thrombocytopenic Human Immunodeficiency Virus Type 1.

Authors:  Nadia El-Menshawy; Mohammed Eissa; Raghada Farag; Ahmed Aboalyazed
Journal:  J Clin Lab Anal       Date:  2015-02-25       Impact factor: 2.352

Review 7.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 8.  Benign ethnic neutropenia.

Authors:  Suheil Albert Atallah-Yunes; Audrey Ready; Peter E Newburger
Journal:  Blood Rev       Date:  2019-06-21       Impact factor: 8.250

Review 9.  DARC and D6: silent partners in chemokine regulation?

Authors:  Chris A H Hansell; Catherine E Hurson; Robert J B Nibbs
Journal:  Immunol Cell Biol       Date:  2010-12-14       Impact factor: 5.126

10.  Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Authors:  Zoltan Beck; Bruce K Brown; Lindsay Wieczorek; Kristina K Peachman; Gary R Matyas; Victoria R Polonis; Mangala Rao; Carl R Alving
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.